A somatostatin-2 receptor antagonist (BIM-23627) improved the catabolic effects of chronic glucocorticoid treatment in rats, partially restoring GH signaling and reducing muscle/bone wasting.
Key findingSomatostatin subtype-2 receptor antagonist BIM-23627 partially reversed glucocorticoid-induced catabolism in rats by reducing somatostatin's GH-inhibi
What the researchers found
Somatostatin subtype-2 receptor antagonist BIM-23627 partially reversed glucocorticoid-induced catabolism in rats by reducing somatostatin's GH-inhibitory tone, improving GH/IGF-1 axis activity and reducing muscle and bone loss from chronic steroids.
Why it matters
Relevant for neuropeptides, hormone-optimization.
How the study worked
animal-study study on neuropeptides, hormone-optimization.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide/biomarker research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat.
Regulatory peptides, 125(1-3), 85-92
Citation
Tulipano, Giovanni; Rossi, Elena; Culler, Michael D; Taylor, John E; Bonadonna, Stefania; Locatelli, Vittorio; Cocchi, Daniela; Giustina, Andrea. (2005). The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat.. Regulatory peptides, 125(1-3), 85-92.